UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
March
5, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
750
Lexington Avenue, 20th
Floor
New
York, New York 10022
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
|
Form
20-F x
|
Form 40-F o |
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes
o
|
No x |
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
Biopharmaceuticals to Present at Oppenheimer’s
“Positioning
Investors for the Next Wave in Pain Management”
Conference
NEW
YORK, NEW YORK, March
5, 2007 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today
that
Ron Bentsur, the Company’s Chief Executive Officer, is scheduled to present
tomorrow at Oppenheimer’s “Positioning Investors for the Next Wave in Pain
Management” Conference. Mr. Bentsur will present an overview of Bicifadine, the
Company’s recently in-licensed late-stage clinical compound for the treatment of
neuropathic pain, in a presentation titled: “Bicifadine - A New Idea for
Neuropathic Pain.” Mr. Bentsur’s presentation will take place on Tuesday, March
6, 2007, at 2:25pm-2:40pm Eastern Standard Time followed by a question and
answer session from 2:55pm-3:15pm., at the Flatotel Hotel in New York City.
A
live
audio webcast of Mr. Bentsur's presentation will be available at:
http://www.wsw.com/webcast/opp/xtl.l/.
An
archived version of the webcast will be available following the conclusion
of
the live presentation.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and
commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL
is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial
in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a
combination of two monoclonal antibodies against the hepatitis C virus -
presently in Phase 1 clinical trials in patients with chronic hepatitis C.
XTL’s
hepatitis C pipeline also includes several families of pre-clinical hepatitis
C
small molecule inhibitors. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional drug candidates.
XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
(NASDAQ: XTLB; LSE: XTL; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(212)-531-5960
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: March 5, 2007 | By: | /s/ Ron Bentsur |
|
Ron Bentsur |
||
|
Chief
Executive Officer
|
||